FLORHAM PARK, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (BeyondSpring or the Company), a clinical-stage global biopharmaceutical company focused on developing...
New Clinical Data from MD Anderson Presented at the Society for Immunotherapy of Cancer™s 38th Annual Meeting80% DCR (disease control rate) in non-radiated tumor with Durable Responses in Heavily...
BeyondSpring Presents Positive Data with Plinabulin for the Prevention of Docetaxel-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer and Breast Cancer at Three Medical Conferences
NEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have a high unmet medical need, today announced data from a poster presentation at the 19th International Myeloma Society Annual Meeting being held August 25-27, 2022, in Los Angeles, California. This is an open label, investigator-initiated study (NCT05130827) conducted at Memorial Sloan Kettering Cancer Center (MSK) that is evaluating the reduction in neutropenia burden with lead asset plinabulin in combination with pegfilgrastim in multiple myeloma (MM) patients who have undergone autologous hematopoietic stem cell transplantation (AHCT) and have received a high dose of melphalan, a type of chemotherapy. To date, plinabulin appears well tolerated, and preliminary data show that only one out of the 10 patients enrolled (10%) had non-engraftment related neutropenic fevers or febrile neutropenia (FN) with plinabulin and pegfilgrastim, compared to a historical number of 60% of FN with standard of care. Enrollment is ongoing, and full trial results will be presented at a later date.
NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) -- BeyondSpring nPharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a nglobal pharmaceutical company focused on the development of cancer ntherapeutics, today announced the presentation of additional analyses nfrom the Phase 3 portion of the PROTECTIVE-2 trial evaluating the ncombination of plinabulin and pegfilgrastim for the prevention of nchemotherapy-induced neutropenia (CIN) in breast cancer patients at the n2021 San Antonio Breast Cancer Symposium (SABCS), held both live and nvirtually from December 7-10, 2021.
The BeyondSpring roller coaster has plunged downward again. While BeyondSpring wowed investors with its phase 3 lung cancer data in August, the FDA found less to like in another indication, rejecting the drug on the grounds that the single registrational trial was too flimsy to show the drug’s benefit.
NEW YORK, Oct. 20, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced the presentation of preclinical data in patient-derived (PDX) cancer models supporting the use of plinabulin in small cell lung cancer (SCLC) at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, held October 7-10, 2021.
Beyondspring’s pledge to file plinabulin with the FDA next year has failed to reassure investors. The group’s shares sank 33% yesterday, after full results from the Dublin-3 trial were presented at Esmo – a stark contrast to the 176% surge Beyondspring enjoyed after toplining the data in August.
Beyondspring’s stock price tripled in August after the New York drug maker said its experimental treatment helped patients with advanced lung cancer live longer. But detailed results presented Monday revealed issues with the conduct and analysis of the clinical trial — leaving the company’s claim of a survival benefit open for debate.
BeyondSpring announced this morning a commercialization and co-development agreement between its Chinese subsidiary Wanchunbulin and China’s Jiangsu Hengrui Pharmaceuticals.